2 assets in Paranasal Sinus Carcinoma

Therapeutic assets addressing Paranasal Sinus Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Paranasal Sinus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Paranasal Sinus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)